Massive data screening is a second opportunity to improve the management of patients with familial hypercholesterolemia phenotype.

Introduction: Familial Hypercholesterolemia (FH) is an autosomal dominant disease with an estimated prevalence between 1/200-250. It is under-treated and underdiagnosed. Massive data screening can increase the detection of patients with FH.